Info

Maxygen, Inc. (Maxygen), incorporated on May 7, 1996, is a biotechnology company involved in the discovery and development of next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. As of December 31, 2007, the Company had three of its next-generation product candidates in clinical or pre-clinical development: MAXY-G34, a granulocyte colony stimulating factor (G-CSF) for the treatment of neutropenia; MAXY-VII, a factor VIIa product for the treatment of hemophilia and possibly acute bleeding conditions, and MAXY-4, a CTLA-4-Ig product for the treatment of rheumatoid arthritis and other immune or autoimmune diseases.(Source: 10-K)